Genetically Modified Human Cell Lines for ADME Toxicology Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug discovery processes face challenges in accurately predicting drug safety and efficacy due to the lack of appropriate human cell models that can mimic human ADME and toxicology processes, leading to unforeseen toxicology issues in human patients despite successful animal testing.
Innovation Solution
Development of genetically modified human cell lines with disrupted expression of ADME/Tox proteins such as ABCG2, achieved through endonuclease-mediated genome editing, to assess the effects of agents on drug absorption, distribution, metabolism, and excretion processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal models are used for toxicology testing, then drug development can proceed with available test systems, but the results do not accurately predict human toxicology outcomes
Solution Approach 1:
The patent creates human cell lines that copy human ADME and toxicology proteins in a controlled environment. By establishing human cell-based test systems that express human-specific proteins (such as human cytochrome P450 enzymes and human ABC transporters), the invention replicates human metabolic and transport processes in vitro, allowing accurate prediction of human drug responses without relying on animal models.
Solution Approach 2:
The patent modifies cellular parameters by introducing or disrupting specific gene expressions in human cell lines. Through techniques such as CRISPR/Cas9 gene editing or overexpression systems, the invention alters the expression levels of ADME proteins and toxicology-related genes in human cells, creating cell lines with defined genetic modifications that reflect human pharmacokinetic and toxicological characteristics.
2Measurement precision
If more human-specific test systems are developed, then predictive accuracy improves, but the complexity of the testing system increases
Solution Approach 1:
The patent divides the complex task of human drug metabolism and toxicology testing into separate, manageable cell line models. Each human cell line is engineered to express or disrupt specific ADME proteins or toxicology pathways individually (e.g., one cell line for CYP3A4 metabolism, another for ABCB1 transport). This segmentation allows researchers to study each protein's function in isolation while maintaining overall system accuracy.
Solution Approach 2:
The patent creates human cell lines that serve multiple functions in drug discovery. These genetically modified human cells can simultaneously assess drug metabolism, transporter interactions, and toxicology endpoints within a single system. The universal human cell background provides a consistent platform that can evaluate multiple drug candidates across different ADME and toxicology parameters, reducing the need for separate specialized test systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These modified cell lines provide a powerful tool for improving preclinical drug discovery by simulating human ADME and toxicology processes, enabling the identification of safe and efficacious compounds by comparing results with wild-type cells.
Implementation Method 1
endonuclease-mediated genome editing
Data Source
Figure 1
Figure 2
AI summary
The present invention provides cells comprising disrupted expression of at least one membrane transporter, drug metabolizing enzyme, xenobiotic sensor, or cellular stress response pathway protein. Also provided are methods for assessing the effect of an agent in the cells disclosed herein relative to comparable control cells.